Trial Profile
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Aug 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms GIDEON
- Sponsors Bayer
- 03 Jul 2021 Results of pooled analysis (n=3575) from GIDEON and OPTIMIS studies assessing Baseline characteristics presented at the 23rd World Congress on Gastrointestinal Cancer
- 01 Mar 2017 Results of evaluation of sorafenib in Chinese patients (n=338) published in the Tumour Biology
- 19 Oct 2016 Results (n=512) of a pooled analysis from the Italian subgroup of GIDEON and from STELLA study assessing safety and efficacy in clinical practice, presented at the 24th United European Gastroenterology Week